2025 Society of Urologic Oncology (SUO) Annual Meeting
SUO 2025 Prostate Cancer
- SUO 2025: Huggins Medal Lecture: What I Did and What I Am Doing
- SUO 2025: Primary Efficacy and Surgical Details in KEYNOTE-905: Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab in Participants with Muscle-invasive Bladder Cancer Who Are Cisplatin-ineligible
- SUO 2025: Emerging Frontiers in Metastatic Prostate Cancer: Approved, Advancing, and Ahead
- SUO 2025: Reducing Over Detection in Prostate Cancer: The Case for Reflex Biomarkers
- SUO 2025: Reducing Over Detection in Prostate Cancer: The Case for Reflex Imaging
SUO 2025 Bladder Cancer
- SUO 2025: INLEXZO™ Monotherapy in Patients with BCG-unresponsive Papillary Disease-only, High-risk NMIBC: 1-year Disease-free Survival Results from SunRISe-1
- SUO 2025: First Results from CORE-008 Cohort A – A Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients with High-risk, BCG-naïve, NMIBC
- SUO 2025: Systemic Therapy & Defining MRD in Metastatic Urothelial Carcinoma
- SUO 2025: Topline Results from BOND-003 Cohort P – A Multinational , Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-risk, Papillary-only, BCG-unresponsive NMIBC
- SUO 2025: The 2025 AUA Hematuria Guidelines: Overview of Recommendations and Risk Stratification
SUO 2025 Kidney Cancer
- SUO 2025: ZIRCON-X: Impact of 89Zr-Girentuximab PET/CT Versus Conventional Imaging on Clinical Decision-Making in Patients with Indeterminate Renal Masses
- SUO 2025: EAU Lecture: Active Surveillance of Renal Tumors: A 20-year Journey
- SUO 2025: Relief of Venous Congestion as a Modifiable Cause of Renal Dysfunction in RCC with IVC Tumor Thrombus: A Comparative Cohort Study
- SUO 2025: Neo-SAbR: A Phase II Trial of Neoadjuvant Stereotactic Ablative Radiotherapy for Caval Thrombus in Newly Diagnosed Renal Cell Carcinoma
- SUO 2025: LITESPARK-004: 5-Year Follow-up of the Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor Belzutifan in Von Hippel-Lindau (VHL) Disease–associated Neoplasms
SUO 2025 Penile, Urethral, Testicular, and Adrenal Cancers
SUO 2025 Upper Tract Urothelial Cancer
SUO 2025 Press Releases
- Johnson & Johnson’s INLEXZO™ (Gemcitabine Intravesical System) Delivers 74 Percent Disease-Free Survival at One Year in BCG-Unresponsive, High-Risk, Papillary-Only NMIBC
- New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
- SUO and Ferring Pharmaceuticals Announce the SUO Non-Muscle Invasive Bladder Cancer (NMIBC) Fellows Research Grant
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting